Any opinion as to why YMI is changing the patient population for the "pivotal" form of this trial? I would think that the strongest position would be to resume testing in the last-ditch population (build on the strong results) rather than moving up into a less-advanced stage using combination therapy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.